ClinicalTrials.gg
TerminatedNCT03445000ALERT-lungUpdated Jul 21, 2026Results posted

ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer

A Phase 2 interventional study of Alectinib in Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Metastatic and Non-small Cell Lung Cancer Recurrent, sponsored by ETOP IBCSG Partners Foundation. Terminated at 19 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by ETOP IBCSG Partners Foundation · Phase 2, Interventional, and Treatment

Why this study was terminated
Low recruitment rate

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 27 studies testing alectinib in Carcinoma, Non-Small-Cell Lung — 7 open to participants now, 14 under way, 4 of them phase 3. alectinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
24th of 27
14 · median 90
Started
2018
with 1 other
Phase 2
9 of 27
4 open now
Registered
14th of 27
by date
Lead sponsor
1 of 27
ETOP IBCSG Partners Foundation

Among the 27 studies testing alectinib in Carcinoma, Non-Small-Cell Lung, this one is the 24th largest by enrollment, is one of 2 that started in 2018, is one of 9 in phase 2, and was the 14th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

7 of the 27 studies testing alectinib in Carcinoma, Non-Small-Cell Lung are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About alectinib

alectinib: first FDA approval 2015 (ALECENSA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing alectinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

A research study to evaluate the activity of alectinib for the Treatment of pretreated patients with advanced NSCLC that have confirmed RETrearrangement.

Read the detailed description

The trial is investigating the efficacy of alectinib in patients with advanced stage RET-rearranged NSCLC, treated with at least one platinum based systemic chemotherapy regimen. Preclinical studies have shown that alectinib, a highly selective next generation ALK inhibitor, has potent anti-tumour activity in RET-rearranged NSCLC. Therapeutically, several multiple kinases inhibitors, are potentially able to inhibit RET kinase function, which has been tested in several unselected NCSLC trials. However, those result were negative and none of the tested drugs was approved for lung cancer treatment.

The ALERT-lung trial is a single arm, phase II trial with the primary objective to assess the efficacy of alectinib in terms of best overall response (OR) assessed by RECIST v1.1 in selected NSCLC patients with RET rearrangement. The secondary objectives are to evaluate secondary measures of clinical efficacy including disease control, progression-free survival (PFS), and overall survival (OS) as well as to assess safety and tolerability of the treatment and to describe the association of primary and secondary outcomes with tumour characteristics.

Alectinib is administered orally, 600 mg, twice per day, until progression, refusal or unacceptable toxicity. Trial treatment may also continue beyond progression, with physician and patient agreement, for as long as the patient may still derive clinical benefit. A total sample size of 44 patients is required.

03

Conditions studied

  • Non-small Cell Lung Cancer
  • Non-small Cell Lung Cancer Metastatic
  • Non-small Cell Lung Cancer Recurrent

Keywords

  • RET-rearrangement
  • advanced NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically documented non-small cell lung carcinoma
  2. Advanced disease defined as recurrent stage IV (according to 8th TNM classification) or recurrent or progressive disease following multimodal therapy (radiation therapy, surgical resection, or definitive chemo-radiation therapy for locally advanced disease)
  3. At least one prior platinum-based systemic regimen: Adjuvant or or definitive platinum-based chemo-radiotherapy treatments are considered as a only if completed less than 6 months before enrolment. Maintenance therapy following platinum doublet-based chemotherapy is not considered a separate regimen of therapy.
  4. RET rearrangement detected by FISH, Nanostring or by parallel-sequencing on FFPE tumour tissue assessed locally.
  5. Availability of FFPE tumour material for central confirmation of RETrearrangement
  6. Measurable or non-measurable, but radiologically evaluable (except for skin lesions) disease according to v1.1 criteria
  7. Age ≥18 years
  8. (ECOG) Performance Status 0-2
  9. >3 months
  10. Adequate haematological function:

    • ≥9 g/dL
    • ≥1.5 ×109/L
    • count ≥100 × 109/L
    • WBC ≥2 ×109/L
  11. Adequate renal function: Calculated ≥45 mL/min (according to Cockcroft-Gault formula)
  12. Adequate liver function:

    • Total ≤2x (except patients with Gilbert Syndrome, who can have total bilirubin ≤3.0 mg/dL)
    • and AST ≤3x ULN (≤5x ULN for patients with concurrent liver ¨ )
  13. Patient capable of proper therapeutic compliance, and accessible to correct followup.
  14. Women of , including women who had their last menstrual period in the last 2 years, must have a negative serum or urine beta HCG pregnancy test within 7 days before enrolment into the trial and within 3 days before alectinib treatment start.
  15. Sexually active men and women of childbearing potential must use an effective method (intrauterine devices without hormones, bilateral tubal occlusion, vasectomized partner or total abstinence) during the trial treatment and for a period of at least 3 months following the last dose of alectinib.
  16. Recovered from any previous therapy related toxicity to Grade ≤1 at date of enrolment (except for recovery to Grade ≤2 of alopecia, fatigue, creatinine increased, lack of appetite or peripheral neuropathy)
  17. Written (IC) for trial treatment must be signed and dated by the patient and the investigator prior to any trial-related intervention.

Exclusion criteria

Exclusion Criteria:

  1. Untreated, active
  2. Carcinomatous meningitis
  3. Any previous (in the past 3 years) or concomitant EXCEPT adequately treated basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or bladder, in situ ductal carcinoma of the breast
  4. Any serious diseases or clinical conditions, including but not limited to uncontrolled active infection and any other serious underlying medical processes, that could affect the patient's capacity to participate in the trial
  5. Liver disease characterized by:

    • or AST >3 × (>5 × ULN for patients with concurrent liver ) confirmed on two consecutive measurements or
    • Impaired excretory function (e.g., hyperbilirubinaemia) or synthetic function or other conditions of decompensated liver disease such as coagulopathy, hepatic encephalopathy, hypoalbuminaemia, ascites, and bleeding from oesophageal varices or
    • Acute viral or active , alcoholic, or other types of acute hepatitis
  6. Patients with baseline symptomatic bradycardia
  7. Previous treatment with any RET TKI or RET targeted therapy.
  8. Known EGFR, ALK, ROS, and BRAF mutation (in addition to RET rearrangement)
  9. Any concurrent systemic anticancer therapy.
  10. Any GI disorder that may affect absorption of oral medications, such as malabsorption syndrome or status post major bowel resection.
  11. History of to any of the additives in the alectinib drug formulation.
  12. Known positivity or AIDS-related illness.
  13. Women who are pregnant or in the period of lactation.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Trial treatment

    Alectinib is administered orally, 600 mg, twice per day (1200 mg per day) until progression, refusal or unacceptable toxicity. Trial treatment may also continue beyond progression, with physician and patient agreement, for as long as the patient may still derive clinical benefit as per investigator decision.

    Drug: Alectinib

Interventions

  • Alectinib is administered orally 600mg (4x150mg capsules), twice per day (8 capsules, total 1200mg daily). The appropriate number of alectinib capsules will be provided to patients to be self-administered at home. Alectinib capsules must be taken at the same time each day with food. If a planned dose of alectinib is missed, patients can take the missed dose up until 6 hours before the next dose.

    Also known as: Alecensa

06

What researchers measure

Primary outcomes

  1. Best Overall Response (BOR)

    Best overall response (OR = CR or PR), per investigator assessment. OR was determined using the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). OR is defined as the best overall response \[Complete Response (disappearance of all target and non-target lesions, no new lesions) or Partial Response (at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum of diameters, no measurable increase in a non-target lesion, no new lesions)\] across all assessment points. Radiological tumour assessments were performed using CT scans.

    Time frame: Evaluated from enrollment through study completion, up to a maximum of 28 months.

Secondary outcomes

  1. Disease Control at 24-weeks

    Best overall response of CR or PR, or SD (or non-CR/non-PD in the case of non-measurable disease only) by RECIST v1.1 criteria. Complete Response (CR): disappearance of all target and non-target lesions and no new lesions detected; Partial Response (PR): at least 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum of diameters (no measurable increase in a non-target lesion and no new lesion detected); Stable disease (SD): at most 20% increase or at most 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum of diameters (no measurable increase in a non-target lesion and no new lesion detected). Radiological tumour assessments were performed using CT scans.

    Time frame: From first documented response (CR, PR, SD, non-CR/non-PD) to 24 weeks or first documented progression or death from any cause, whichever came first, assessed every 8 weeks (±4 days).

  2. Progression-free Survival (PFS)

    Progression-free survival time was measured from the date of enrolment until documented progression or death from any cause, whichever came first. PFS is assessed according to RECIST 1.1 criteria. Progressive disease: at least a 20% increase in the sum of the longest diameter of target lesions taking as reference the baseline sum of diameters, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: Evaluated from enrollment through study completion, up to a maximum of 28 months.

  3. Overall Survival (OS)

    Overall survival time is measured from the date of enrolment until death from any cause.

    Time frame: Evaluated from enrollment through study completion, up to a maximum of 28 months.

  4. Number of Patients Experienced Adverse Events

    The safety and tolerability of alectinib treatment is assessed through analysis of the worst grade of toxicity/adverse events according to CTCAE v4.0 criteria observed over the whole treatment period.

    Time frame: Evaluated from enrollment through study completion, up to a maximum of 28 months.

07

Results

Posted Mar 26, 2025

Participant flow

Recruitment period ranged from November 2018 to April 2020.

Participant flow — Overall Study
MilestoneTrial Treatment
Started14
Completed0
Not completed14
Withdrew: Disease progression8
Withdrew: Adverse event3
Withdrew: Death2
Withdrew: Physician decision1

Outcome measures

PrimaryBest Overall Response (BOR)

Best overall response (OR = CR or PR), per investigator assessment. OR was determined using the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). OR is defined as the best overall response \[Complete Response (disappearance of all target and non-target lesions, no new lesions) or Partial Response (at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum of diameters, no measurable increase in a non-target lesion, no new lesions)\] across all assessment points. Radiological tumour assessments were performed using CT scans.

Time frame:
Evaluated from enrollment through study completion, up to a maximum of 28 months.
Reported as:
Count of participants · Participants
Best Overall Response (BOR)
ParticipantsTrial Treatment
Complete response0
Partial response0
Stable disease9
Non-Complete response/ Non-Progressive disease (in case of non-measurable disease only)1
Progressive disease2
Not evaluable1
SecondaryDisease Control at 24-weeks

Best overall response of CR or PR, or SD (or non-CR/non-PD in the case of non-measurable disease only) by RECIST v1.1 criteria. Complete Response (CR): disappearance of all target and non-target lesions and no new lesions detected; Partial Response (PR): at least 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum of diameters (no measurable increase in a non-target lesion and no new lesion detected); Stable disease (SD): at most 20% increase or at most 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum of diameters (no measurable increase in a non-target lesion and no new lesion detected). Radiological tumour assessments were performed using CT scans.

Time frame:
From first documented response (CR, PR, SD, non-CR/non-PD) to 24 weeks or first documented progression or death from any cause, whichever came first, assessed every 8 weeks (±4 days).
Reported as:
Number · percentage of patients
Disease Control at 24-weeks
percentage of patientsTrial Treatment
Disease Control at 24-weeks23.1 (5.0 to 53.8)
SecondaryProgression-free Survival (PFS)

Progression-free survival time was measured from the date of enrolment until documented progression or death from any cause, whichever came first. PFS is assessed according to RECIST 1.1 criteria. Progressive disease: at least a 20% increase in the sum of the longest diameter of target lesions taking as reference the baseline sum of diameters, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
Evaluated from enrollment through study completion, up to a maximum of 28 months.
Reported as:
Median · months
Progression-free Survival (PFS)
monthsTrial Treatment
Progression-free Survival (PFS)3.7 (1.8 to 7.3)
SecondaryOverall Survival (OS)

Overall survival time is measured from the date of enrolment until death from any cause.

Time frame:
Evaluated from enrollment through study completion, up to a maximum of 28 months.
Reported as:
Median · months
Overall Survival (OS)
monthsTrial Treatment
Overall Survival (OS)NA (13.8 to NA)
SecondaryNumber of Patients Experienced Adverse Events

The safety and tolerability of alectinib treatment is assessed through analysis of the worst grade of toxicity/adverse events according to CTCAE v4.0 criteria observed over the whole treatment period.

Time frame:
Evaluated from enrollment through study completion, up to a maximum of 28 months.
Reported as:
Count of participants · Participants
Number of Patients Experienced Adverse Events
ParticipantsTrial Treatment
Experienced adverse event(s)14
Experienced serious adverse event(s)4

Adverse events

Collected over Continuously from the date of Informed Consent signature until 30 days after all treatments discontinuation, up to approximately 28 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trial Treatment3/14 (21.4%)4/14 (28.6%)14/14 (100%)
Most frequent serious events
Most frequent serious events
EventTrial Treatment
Sudden death not otherwise specified (NOS)General disorders1/14
DyspneaRespiratory, thoracic and mediastinal disorders1/14
Soft tissue infectionInfections and infestations1/14
Adrenal insufficiencyEndocrine disorders1/14
Thromboembolic eventVascular disorders1/14
Most frequent other events
Showing 10 of 58
Most frequent other events
EventTrial Treatment
FatigueGeneral disorders6/14
AnemiaBlood and lymphatic system disorders6/14
ConstipationGastrointestinal disorders4/14
FeverGeneral disorders3/14
General disorders and administration site conditions - OtherGeneral disorders3/14
PainGeneral disorders3/14
CPK increasedInvestigations3/14
Dry skinSkin and subcutaneous tissue disorders3/14
Erythema multiformeSkin and subcutaneous tissue disorders3/14
HeadacheNervous system disorders3/14

Baseline characteristics

Age, Continuous
Age, Continuous(years)Trial Treatment
Median60.6 (38.0 to 81.4)
Age, Customized
Age, Customized(Participants)Trial Treatment
≤ 60 years6
>60 years8
Sex: Female, Male
Sex: Female, Male(Participants)Trial Treatment
Female10
Male4
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Trial Treatment
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White14
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Trial Treatment
Netherlands6
Belgium1
Italy2
Spain5
ECOG Performance Status
ECOG Performance Status(Participants)Trial Treatment
04
110
Smoking status
Smoking status(Participants)Trial Treatment
Current1
Former (≥ 100 cigarettes in the past during the whole life)3
Never (0-99 cigarettes during the whole life)10
08

Study locations

19 sites
  • Institut Jules Bordet
    Brussels, Belgium
  • St. James Hospital
    Dublin, Ireland
  • IRCCS Instituto Tumori Giovanni Paolo II
    Bari, Italy
  • Instituto Europeo di Oncologia (IEO)
    Milan, Italy
  • University Hospital of Turin
    Turin, Italy
  • Universita di Verona
    Verona, Italy
  • The Netherlands Cancer Institute Amsterdam
    Amsterdam, Netherlands
  • University Medical Center Maastricht
    Maastricht, Netherlands
  • Hospital Teresa Herrara
    A Coruña, Spain
  • Hospital general de Alicante
    Alicante, Spain
  • Vall d'Hebron University Hospital
    Barcelona, 08035, Spain
  • Hospital Quirón Dexeus
    Barcelona, Spain
  • Hospital Sant Pau
    Barcelona, Spain
  • Hospital Puerta de Hierro
    Madrid, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, Spain
  • Hospital Regional Universitario Carlos Haya
    Málaga, Spain
  • HFR Fribourg
    Fribourg, Switzerland
  • Hôpital Universitaire de Genève
    Geneva, Switzerland
  • UniversitatSpital Zurich
    Zurich, Switzerland
09

References and documents

Publications

  • Gainor JF, Shaw AT. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist. 2013;18(7):865-75. doi: 10.1634/theoncologist.2013-0095. Epub 2013 Jun 28. PubMed 23814043 ↗
  • Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, Lim Choi Y, Satoh Y, Okumura S, Nakagawa K, Mano H, Ishikawa Y. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012 Feb 12;18(3):378-81. doi: 10.1038/nm.2658. PubMed 22327623 ↗
  • Lin JJ, Kennedy E, Sequist LV, Brastianos PK, Goodwin KE, Stevens S, Wanat AC, Stober LL, Digumarthy SR, Engelman JA, Shaw AT, Gainor JF. Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol. 2016 Nov;11(11):2027-2032. doi: 10.1016/j.jtho.2016.08.126. Epub 2016 Aug 17. PubMed 27544060 ↗
  • Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Fruh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazieres J, Drilon A. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol. 2017 May 1;35(13):1403-1410. doi: 10.1200/JCO.2016.70.9352. Epub 2017 Mar 13. PubMed 28447912 ↗
  • Kodama T, Tsukaguchi T, Satoh Y, Yoshida M, Watanabe Y, Kondoh O, Sakamoto H. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. Mol Cancer Ther. 2014 Dec;13(12):2910-8. doi: 10.1158/1535-7163.MCT-14-0274. Epub 2014 Oct 27. PubMed 25349307 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Mar 2021, 28 months.

Results were first posted in Mar 2025, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2018
First posted
Feb 26, 2018
StartActual
Nov 6, 2018
Primary completionActual
Mar 31, 2021
CompletionActual
Mar 31, 2021
Results first posted
Mar 26, 2025
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03445000
Lead sponsor
ETOP IBCSG Partners Foundation
Collaborators
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 26, 2018
Start date
Nov 6, 2018
Primary completion
Mar 31, 2021
Completion
Mar 31, 2021
Results posted
Mar 26, 2025
Last update
Jul 21, 2026

Study contacts

Enriqueta Felip, MD-PhD
study chair · Vall d'Hebron University Hospital
Jürgen Wolf, MD-PhD
study chair · University Hospital Cologne
Egbert F. Smith, MD-PhD
study chair · The Netherlands Cancer Institute Amsterdam

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alectinib

Start the discussion